Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
暂无分享,去创建一个
H. Beltran | J. Mosquera | Yipeng Wang | V. Conteduca | M. Sigouros | A. Jendrisak | Jerry Lee | R. Dittamore | Sheng-Yu Ku | J. Manohar | J. Schonhoft | Cole Gilbertson | R. Wenstrup | M. Slade | L. Fernandez | Angel Dago-Rodriquez
[1] S. Gregory,et al. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide , 2021, Clinical Cancer Research.
[2] Pham Quoc Thang,et al. Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers , 2021, British Journal of Cancer.
[3] X. Qiu,et al. Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases , 2021, Frontiers in Oncology.
[4] E. Lobenhofer,et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer , 2020, Clinical Cancer Research.
[5] H. Beltran,et al. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations , 2020, JAMA network open.
[6] J. Hicks,et al. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer , 2020, Clinical Cancer Research.
[7] O. Elemento,et al. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy , 2020, Molecular Cancer Therapeutics.
[8] O. Elemento,et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. , 2020, The Journal of clinical investigation.
[9] O. Elemento,et al. Clinical features of neuroendocrine prostate cancer. , 2019, European journal of cancer.
[10] N. Navin,et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. , 2019, The Lancet. Oncology.
[11] M. Loda,et al. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance , 2019, Clinical Cancer Research.
[12] Yi Mi Wu,et al. Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.
[13] O. Elemento,et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer , 2019, Science Translational Medicine.
[14] Joshua M. Stuart,et al. Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039)) , 2018 .
[15] Joshua M. Stuart,et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Joshua M. Stuart,et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.
[17] C. Rudin,et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.
[18] Yipeng Wang,et al. Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis , 2016, PloS one.
[19] David S. K. Lu,et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.
[20] Oliver Sartor,et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Alessandro Romanel,et al. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care , 2016, npj Genomic Medicine.
[22] C. Rudin,et al. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer , 2016, Clinical Cancer Research.
[23] Matteo Benelli,et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.
[24] H. Beltran,et al. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer , 2015, Clinical Cancer Research.
[25] Gail Mandel,et al. A High-Resolution Imaging Approach to Investigate Chromatin Architecture in Complex Tissues , 2015, Cell.
[26] C. Rudin,et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo , 2015, Science Translational Medicine.
[27] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[28] David C. Smith,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[29] M. Nykter,et al. The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.
[30] M. Landers,et al. Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization , 2015, Journal of circulating biomarkers.
[31] M. Rubin,et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.
[32] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[33] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .